Pipeline
CYT-108 is designed to be 200% more potent than natural A2M and to block the main enzyme families that break down cartilage, including MMP-13 and ADAMTS-5.
Because it is made in the lab rather than taken from a patient's blood, every dose can be made to the same specification.
Delivered by injection
directly into the joint, for high concentration where it's needed and low exposure elsewhere.
Designed to trap destructive proteases
and dampen the inflammatory signals that keep the cycle going.
Aimed at reducing pain and inflammation
while slowing cartilage breakdown. Whether it does this in people is what clinical trials are designed to test.
Clinical Progress
June 2024
First patient dosed in a first-in-human Phase 1 study in knee osteoarthritis.
October 2025
Phase 1 database locked.
March 2026
Phase 1 Clinical Study Report completed.
Coming
Next
A Phase 1b/2a trial designed to look for signs of disease modification.
Investor Presentation
Cytonics: a biotech rebellion
Get updates on CYT-108 and the science behind it.

The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.
This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
© 2026 Cytonics Corporation. All rights reserved.